Hyperlipidemia Drugss

Question 1

High intensity: Atorvastatin

Answer 1

(Lipitor): 40-80 mg

High Intensity Statin therapy: Lower LDL ~50%

Question 2

High intensity: Rosuvastatin

Answer 2

(Crestor): 20-40 mg

High Intensity Statin therapy: Lower LDL ~50%

Question 3

Moderate Intensity: Atorvastatin

Answer 3

Lipitor: 10-20 mg

Moderate intensity drug therapy: Lower LDL 30-50%

Question 4

Moderate Intensity: Rosuvastatin

Answer 4

Crestor: 5-10mg

Moderate intensity drug therapy: Lower LDL 30-50%

Question 5

Moderate Intensity: Simvastatin

Answer 5

(Zocor): 20-40 mg

Moderate intensity drug therapy: Lower LDL 30-50%

Question 6

Moderate intensity: Pravastatin

Answer 6

Pravachol: 40-80 mg

Moderate intensity drug therapy: Lower LDL 30-50%

Question 7

Moderate intensity: Lovastatin

Answer 7

Mevacor: 40 mg

Moderate intensity drug therapy: Lower LDL 30-50%

Question 8

Low intensity: Simvastatin

Answer 8

Zocor: 10 mg

Low-intensity statin therapy: Lower LDL < 30%

Question 9

Low intensity: Pravastatin

Answer 9

(Pravachol): 10-20 mg

Low-intensity statin therapy: Lower LDL < 30%

Question 10

Low intensity: Lovastatin

Answer 10

(Mevacor): 20 mg

Low-intensity statin therapy: Lower LDL < 30%

Question 11

Ezetimbe

Answer 11

(Zetia)- 10 mg
MOA: inhibits CHOL transporters at the intestinal border and thereby inhibiting intestinal absorption of dietary and biliary CHOL

Question 12

Cholestyramine

Answer 12

(prevalite)
Bile-acid Binding Resins
MOA: forms a non-absorbable complex w/ bile acids, which increases fecal loss of bile salt bound LDL CHOL and increases LDL receptor for LDL uptake

Question 13

Colesevelam

Answer 13

(Welchol)
Bile-acid Binding Resins
MOA: forms a non-absorbable complex w/ bile acids, which increases fecal loss of bile salt bound LDL CHOL and increases LDL receptor for LDL uptake

Question 14

Colestipol

Answer 14

(Colestid)
Bile-acid Binding Resins
MOA: forms a non-absorbable complex w/ bile acids, which increases fecal loss of bile salt bound LDL CHOL and increases LDL receptor for LDL uptake

Question 15

Niacin

Answer 15

(Vitamin B3)
MOA: inhibits release of FFA from adipose tissue and increases lipoprotein lipases, to increase chylomicron tg removal from the plasma

Question 16

Alirocumab

Answer 16

(praluent)
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Aka PCSK9 inhibitors
MOA: Binds to LDL-R on hepatocyte surface, leading to decreased LDL-R and increased plasma CHOL levels

Question 17

Evolocumab

Answer 17

(Repatha)
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Aka PCSK9 inhibitors
MOA: Binds to LDL-R on hepatocyte surface, leading to decreased LDL-R and increased plasma CHOL levels

Question 18

Gemfibrozil

Answer 18

(Lopid)
Fibric Acid Derivatives
MOA: perioxisome proliferative-activated receptor-apha agonists that increase VLDL catabolism, FA oxidation, and elimination of TG rich particles

Question 19

Fenofibrate

Answer 19

(Fenoglide, fibricor, Lofibra)
Fibric Acid Derivatives
MOA: perioxisome proliferative-activated receptor-apha agonists that increase VLDL catabolism, FA oxidation, and elimination of TG rich particles

Question 20

Statins MOA:

Answer 20

• inhibit hydroxylmethylglutaryl coA (rate-limiting enzyme in CHOL synthesis)
• increased LDL receptors for removal